Retina/Vitreous: Recent Episodes
ReachMD
Host: Rishi P. Singh, MD
Host: Mark R. Barakat, MD
Host: Arshad M. Khanani, MD, MA
Host: Christina Y. Weng, MD, MBA
This program will focus on the clinical trial and real-world data about the novel and emerging therapies for the treatment of dry age-related macular degeneration, wet age-related macular degeneration, diabetic retinopathy, and diabetic macular edema and how these therapies may be integrated into real-world clinical practice.
Host: Christina Y. Weng, MD, MBA
Guest: David Eichenbaum, MD
This discussion with Program Chair Christina Y. Weng, MD, MBA, and David A Eichenbaum, MD, includes a case study that highlights challenges with managing diabetic eye disease during the COVID era and how longer duration therapies could be beneficial.
Drs. Weng and Eichenbaum also converse about the latest data on pipeline therapies for diabetic macular edema, including faricimab, KSI-301, and OPT-302.
Host: Christina Y. Weng, MD, MBA
Guest: Basil K. Williams Jr, MD
In this video case discussion, Program Chair Christina Y. Weng, MD, MBA, and Basil K. Williams Jr, MD, review details of a patient with wet age-related macular degeneration treated during the COVID-19 pandemic. This case highlights the need for increased durability of treatment options.
Drs. Weng and Williams also discuss the latest data on two investigational anti-VEGFs: an antibody biopolymer conjugate and a pan-VEGF plus placental growth factor inhibitor.
Host: Christina Y. Weng, MD, MBA
Guest: Glenn Yiu, MD, PhD
This discussion with Program Chair Christina Y. Weng, MD, MBA, and Glenn Yiu, MD, PhD, includes a case study that highlights challenges with managing diabetic eye disease during the COVID era and how longer duration therapies could be beneficial.
Drs. Weng and Yiu also converse about the latest data on pipeline therapies for diabetic macular edema, including high-dose aflibercept & gene therapy.
Host: Christina Y. Weng, MD, MBA
Guest: Sophie J. Bakri, MD
This discussion with Program Chair Christina Y. Weng, MD, MBA, and Sophie J. Bakri, MD, includes a case study that highlights challenges with managing diabetic eye disease during the COVID era and how longer duration therapies could be beneficial.
Drs. Weng and Bakri also converse about the latest data on pipeline therapies for diabetic macular edema, including brolucizumab & PDS.
Host: Christina Y. Weng, MD, MBA
Guest: Diana Do, MD
In this video case discussion, Program Chair Christina Y. Weng, MD, MBA, and Diana V. Do, MD, review pipeline therapies for wet age-related macular degeneration. Drs. Do and Weng assess challenging cases and focus specifically on how specific investigative therapies that target VEGF-A, C and D may have the potential to extend treatment intervals.
Host: Christina Y. Weng, MD, MBA
Guest: Peter A. Campochiaro, MD
In this video case discussion, Program Chair Christina Y. Weng, MD, MBA, and Peter A. Campochiaro, MD, review pipeline therapies for wet age-related macular degeneration. The faculty review challenging cases that would have potentially different outcomes with investigative therapies such as gene therapy and a novel, long-acting drug delivery system.
Host: Christina Y. Weng, MD, MBA
Guest: Margaret A. Chang, MD, MS
What are the critical steps to implantation and refill of the PDS? Join Dr. Margaret Chang and Dr. Christina Weng to discover the nuances that retina surgeons need to know about to optimize success and minimize patient risk.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nick Kusnezov, MD
Can you balance locum tenens with a full-time career? To answer that question, Dr. Charles Turck is joined by board-certified orthopedic surgeon, Dr. Nicholas Kusnezov, to walk us through his journey from joining the military to locum tenens.
Host: Jennifer Caudle, DO
Guest: Roni Devlin, MD
As rates of burnout continue to rise in the healthcare community, how can help our female physicians combat it? Dr. Jennifer Caudle joins Infectious Disease Specialist, Dr. Roni Devlin, to discuss how we can prevent burnout for female physicians.
Host: Jennifer Caudle, DO
Guest: Maurice G. Sholas, MD, PhD
After years of serving the New Orleans community, one physician decided to pursue locum tenens work. Dr. Jennifer Caudle joins Dr. Maurice Sholas, a pediatric physical rehabilitation physician, to share his experiences with locum tenens and in New Orleans.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Samantha Conroy, MD
Locum tenens can improve quality of care around the globe—especially in remote and underserved communities. To share how, Dr. Paul Doghramji joins Dr. Samantha Conroy, a family practice obstetrician to share her experiences working as a locum tenens obstetrician in underserved communities.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: John J. Russell, MD
Guest: Joseph E. Bavaria, MD
Featuring a wide range of disciplines and a new approach to comprehensive care, what do we need to know about the Aorta Center at Penn Medicine? Dr. John Russell is joined by Dr. Joseph E. Bavaria to dive into this aortic program and discuss a new approach to comprehensive care.
Host: Ruth S. Weinstock, MD, PhD
Guest: Susan B. Bressler, MD
Guest: Mark Dunbar, OD, FAAO
With the increasing prevalence of diabetes in the United States, more individuals are at risk of losing their vision due to diabetic retinopathy every day. Fortunately, research is improving our understanding of this disease. But what does the latest information mean for our patients?
Hear Dr. Susan Bressler, Dr. Mark Dunbar, and Dr. Ruth Weinstock share their perspectives as multidisciplinary specialists treating these patients. Find out what the evidence shows and how timely referral, early diagnosis, and appropriate treatment can prevent the vision-threatening complications of diabetes.
Host: Rahul N. Khurana, MD
Guest: Jennifer K. Sun, MD, MPH
The results from the Protocol W and PANORAMA clinical trials have sparked a lot of talk in the retina community about what the data really mean. So how should physicians interpret these data, and what is changing for their patients with diabetic retinopathy?
Find out in this activity as Dr. Rahul Khurana and Dr. Jennifer Sun review the findings from both trials and discuss if treatment with anti-VEGF really improves outcomes for patients with moderate to severe NPDR.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kathryn Gallagher, MS, RN, BSN
Guest: Kate Newcomb-DeSanto, MSN, RN, MSW
What does Penn Medicine’s newly-opened patient room facility have to offer? Dr. Charles Turck is joined by Penn Medicine Clinical Advisors Kathy Gallagher and Kate Newcomb-DeSanto to discuss the new pavilion and how it's revolutionizing patient care.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sandy Marks
Guest: Kim Horvath, JD
Guest: Kyle Thomson, JD
With telehealth services expanding during the COVID-19 pandemic, has our access to them changed? To better understand this, Dr. Charles Turck meets with Sandy Marks, Kim Horvath, and Kyle Thomson from the AMA to explore what’s been done to provide Medicare coverage during a public health emergency and what’s on the horizon for telehealth access.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Emily Carroll, JD, MSW
The No Surprises Act aims to protect consumers from surprise medical bills. But how exactly does it go about doing that, and what’s the current status of its implementation? Joining Dr. Charles Turck to share progress and challenges associated with the No Surprises Act is Ms. Emily Carroll, a senior legislative attorney for the American Medical Association's Advocacy Resource Center.
Host: Jennifer Caudle, DO
Guest: Sarah Ali, MD
From working in a big city to taking on an assignment in a small mountain village, Dr. Sarah Ali from the Ventura County Medical Center joins Dr. Jennifer Caudle to talk about her adventures abroad with locum tenens and share key lessons she learned along the way.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Mojgan Saber, MD
Can Locum Tenens be an option for healthcare professionals just completing their residency? Dr. Paul Doghramji is joined by Dr. Mojgan Saber to share her own experience as well as tips and tricks for residents looking at Locum Tenens right after residency.
Host: Charles P. Vega, MD
Guest: Lionel Phillips, MBA
Learn why diversity in clinical trials is so important to community health. Two experts discuss the key role that trusted messengers play in enrollment, why it is critical to break the cycle of medical mistrust, and the downstream effect of a lack of diversity in clinical trials.
Host: Charles P. Vega, MD
Guest: Candice Taylor Lucas, MD, MPH, FAAP
What is cultural humility, and how can it be incorporated into clinical practice? How does your patient's culture impact their health behaviors, and why does your culture matter?
Listen in as two leading experts navigate concerns surrounding cultural humility and emphasize the importance of empathy, awareness, and advocacy. Discover ways to integrate small but important changes into your clinical practice to help bridge communication gaps and enable your patients to thrive.
Host: Charles P. Vega, MD
Guest: Sateria Venable
Regional healthcare disparities are biases that are based on where people live. Are your patients’ treatment options being impacted and limited by their geographical location? Join us as our two experts discuss how to support broader policy issues and highlight the importance of diagnostic algorithms that have been developed with diverse input. These steps may be of value in your clinical practice to ensure all patients have equal access to care regardless of their epidemiologic, socioeconomic, or insurance circumstances.
Host: Charles P. Vega, MD
Guest: Robert O. Roswell, MD, FACC, FACP
Diversifying our physician workforce so that it is more racially, ethnically, and geographically balanced can ultimately have a positive impact on community health. Join us as two experts discuss how pipeline programs reaching children as early as elementary school can help ensure workplace diversity. Also find out how clinicians can be advocates for their patients by helping to disentangle them from structural inequities and working towards policy changes. There’s a lot than can be done to provide more balanced care, but we need to look beyond simple fixes to the root causes of the issues. So find your bandwidth – that’s what you can do today – and discover why it’s so important to move upstream to solve the problems manifesting downstream.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: William Tarver, MD
Guest: Tyson Brunstetter, PhD, MBA
Since 2012, at least 27 astronauts have been diagnosed with spaceflight-associated neuro-ocular syndrome, but where does this health threat land now? Joining Dr. Andrew Wilner to discuss this out-of-this-world health threat is Captain Tyson Brunsteller and Dr. William Tarver from NASA.
[Read the Article]
Proliferative diabetic retinopathy (PDR) is a leading cause of vision loss in patients with diabetes, resulting in up to 24,000 cases of blindness each year in the United States. Laser therapy has been the most common treatment used to help reduce severe vision loss, but the procedure has many side effects including permanent loss of peripheral vision and swelling of the retina.
A group of researchers from across the US tested an alternative treatment using an injectable medication called ranibizumab, to see if it would be as effective as the laser therapy. They studied more than 300 patients with PDR, assigning them to either receive standard laser therapy or an injection into the eye. In total, they treated close to 400 eyes.
Outcomes, especially loss of vision, were compared at two years. Over the two year period, researchers found that patients receiving the injections of medication had fewer side effects and did somewhat better in terms of vision loss than those who received laser therapy.
[Watch more videos of The JAMA Report]
Host: Jennifer Caudle, DO
Dr. Jennifer Caudle welcomes Dr. Patrick Spencer, Chairman of the Department of Ophthalmology at Grandview Medical Center in Dayton, Ohio. Their discussion centers on primary care manifestations of sickle cell retinopathy, from early to late-stage presentations and the gold standard treatment approaches along this disease course.
Host: Roy Levit, MD
Guest: Alan Ruby, MD
The standard treatment for proliferative and non-proliferative diabetic retinopathy is laser photocoagulation, but novel methods, including injectable steroids or anti-vascular endothelial growth factor, are also showing promise. What tests can help opthamologists determine the area of leakage in the eye that needs treatment? How soon after surgery will patients see a change in their vision? Dr. Alan Ruby, opthamologist and clinical assistant professor of biomedical sciences at the Eye Research Institute at Oakland University, in Rochester, Michigan, discusses ways to maximize the overall visual outcome for patients with diabetic retinopathy. How can diabetic retinopathy be prevented? Dr. Roy Levit hosts.
Host: Roy Levit, MD
Guest: Alan Ruby, MD
The eyes can yield clues to vascular issues elsewhere in the body. How can the two forms of diabetic retinopathy, which are non-proliferative and proliferative, affect vision, and how might retinopathy be associated with somatic effects resulting from diabetes? Dr. Alan Ruby, opthamologist and clinical assistant professor of biomedical sciences at the Eye Research Institute at Oakland University, in Rochester, Michigan, discusses the correlation between diabetic retinopathy and complications throughout the body. Can tight control of diabetes affect the progression or regression of retinopathy? What can physicians caring for patients with diabetes do to identify vision changes early on, and potentially reduce the risk of later complications? Dr. Roy Levit hosts.
Host: Roy Levit, MD
Guest: Saad Shaikh, MD
Although floaters in one's vision are common, this symptom can be a key indicator of a retinal tear or detachment. What is the incidence of retinal detachment in the U.S., and when should a primary care physician suspect this condition? Dr. Saad Shaikh, associate professor and member of the teaching faculty at the University of Central Florida College of Medicine in Orlando, and assistant professor at the University of South Florida, College of Medicine and at the Florida State College of Medicine, discusses the development of retinal detachments, risk factors, and the techniques used to correct the condition. Dr. Roy Levit hosts.
Host: Roy Levit, MD
Guest: Allen Verne, MD
What are the advantages to using private practices, as opposed to academic institutions, for testing medications? Dr. Allen Verne, president of the American Retina Foundation and founder of the Bay Area Retina Associates, discusses in-office drug studies he is involved in, including one on diabetic retinopathy and another on photodynamic therapy, and why these studies can be particularly useful in determining the most effective treatments for patients with retinal conditions. Dr. Verne also discusses the process of separating the interests of the pharmaceutical companies sponsoring studies and those participating in the study. What are the financial and time costs to the practices involved in in-office medication studies? Dr. Roy Levit hosts.
Host: Steven Edelman, MD
Guest: Paul Tornambe, MD
Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness in American adults. Join host Dr. Steven Edelman and his guest, ophthalmologist Dr. Paul Tornambe, an instructor in the departments of ophthalmology and family practice at the University of California, San Diego, as they discuss early diagnosis, tele-health and the exciting new VEGF inhibitors treatment of diabetic macular edema.
Host: Jennifer Shu, MD, FAAP
Guest: David Abramson, MD
Survival rates for retinoblastoma now approach 100 percent, but in years past, enucleation was the only sure way to cure this rare pediatric malignancy. We're now seeing advances in chemotherapy that not only spare the child's eye, but can preserve vision as well. What makes this chemotherapy regimen so effective, and how can we build on its effectiveness to enhance the vision and the livelihood of children affected by retinoblastoma? Dr. David Abramson, chief of the ophthalmic oncology service at Memorial Sloan-Kettering Cancer Center in New York, joins host Dr. Jennifer Shu to talk about the breadth of retinoblastoma research that has helped us take important strides toward remediation of this disease.
Host: Roy Levit, MD
Guest: Allen Ho, MD
What are macular holes and macular pucker, and how do we treat these conditions? Host Dr. Roy Levit welcomes Dr. Allen Ho, professor of ophthalmology and an attending surgeon in the Retina Service at the Wills Eye Institute in Philadelphia, to discuss back-of-the-eye vitrectomy for the treatment of macular hole and macular pucker. Before this surgical procedure, we had no cure for these diagnoses.
Host: Bruce Bloom, DDS, JD
Guest: Mary Elizabeth Hartnett, MD
Almost a third of all type I and type II diabetics develop macular edema. Join host Dr. Bruce Bloom and his guest, ophthalmologist, researcher and vitreo-retinal surgeon Dr. Mary Elizabeth Hartnett, professor of opthamology at the University of North Carolina at Chapel Hill School of Medicine, as they discuss the etiology and treatment of diabetic macular edema.
Host: Roy Levit, MD
Guest: Mark Humayun, MD
Microelectronic implants are restoring vision to the blind.Dr. Mark Humayun discusses with host Dr. Roy Levit the workings of the artificial retina and explains the surgical procedure to implant the device in the eye. The first generation of the implant only has 16 pixels while the second generation has 62 pixels. Dr. Humayun explains how the subjects who have the implant can initially see spots of light, but that the brain over time can fill in the details and many patients are able to see objects, motion and color. At this time, the implants are available only as a part of the clinical trial to subjects who are completely blind as a result of retinitis pigmentosa.
Host: Roy Levit, MD
Dr. Richard Rosen, surgeon director for the department of ophthalmology and director of ophthalmic research in the Advanced Imaging Center at New York Eye and Ear Infirmary, joins host Dr. Roy Levit to discuss technologies and methods to examine the retina.
Host: Roy Levit, MD
Guest: Cliff Ratner, MD
Dr. Roy Levit welcomes Dr. Cliff Ratner to the Revealing Retina. Dr. Ratner did his residency at Harkness Eye Institute and a 2 Year Retina Fellowship at Wilmer Institute at Johns Hopkins. He has been in private practice for 25 years and is the founder of The Retina Practice of White Plains in New York. With his vast experience and expertise, he will talk about how much has changed and is currently changing in the treatment for Wet Macular Degeneration.
Host: Larry Kaskel, MD
Guest: Elizabeth Tieman, MD
Work-life balance: how many of us can say we have it, let alone come close to having it? Board-certified radiologist Dr. Betsy Tieman is one healthcare professional who can say she achieved work-life balance by leaving private practice where she was working 14 hours a day to take advantage of locum tenens work, which also enabled her to train and compete in triathlons.